Wachter, Rolf

[["dc.bibliographiccitation.firstpage","658"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","ESC Heart Failure"],["dc.bibliographiccitation.lastpage","666"],["dc.bibliographiccitation.volume","6"],["dc.contributor.author","Schertz, Anna"],["dc.contributor.author","Herbeck Belnap, Birgit"],["dc.contributor.author","Chavanon, Mira‐Lynn"],["dc.contributor.author","Edelmann, Frank"],["dc.contributor.author","Wachter, Rolf"],["dc.contributor.author","Herrmann-Lingen, Christoph"],["dc.date.accessioned","2020-12-10T14:06:10Z"],["dc.date.available","2020-12-10T14:06:10Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1002/ehf2.12436"],["dc.identifier.eissn","2055-5822"],["dc.identifier.issn","2055-5822"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16561"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/69805"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.title","Motivational interviewing can support physical activity in elderly patients with diastolic heart failure: results from a pilot study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","998"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","European Journal of Heart Failure"],["dc.bibliographiccitation.lastpage","1007"],["dc.bibliographiccitation.volume","21"],["dc.contributor.author","Wachter, Rolf"],["dc.contributor.author","Senni, Michele"],["dc.contributor.author","Belohlavek, Jan"],["dc.contributor.author","Straburzynska‐Migaj, Ewa"],["dc.contributor.author","Witte, Klaus K."],["dc.contributor.author","Kobalava, Zhanna"],["dc.contributor.author","Fonseca, Candida"],["dc.contributor.author","Goncalvesova, Eva"],["dc.contributor.author","Cavusoglu, Yuksel"],["dc.contributor.author","Fernandez, Alberto"],["dc.contributor.author","Karabsheh, Shadi"],["dc.date.accessioned","2020-12-10T14:06:17Z"],["dc.date.available","2020-12-10T14:06:17Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1002/ejhf.1498"],["dc.identifier.eissn","1879-0844"],["dc.identifier.issn","1388-9842"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16673"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/69843"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","14"],["dc.bibliographiccitation.journal","Journal of Cardiothoracic Surgery"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Bireta, Christian"],["dc.contributor.author","Tirilomis, Theodor"],["dc.contributor.author","Grossmann, Marius"],["dc.contributor.author","Unsoeld, Bernhard W."],["dc.contributor.author","Wachter, R. Rolf"],["dc.contributor.author","Perl, Thorsten"],["dc.contributor.author","Jebran, Ahmad Fawad"],["dc.contributor.author","Schoendube, Friedrich Albert"],["dc.contributor.author","Popov, Aron Frederik"],["dc.date.accessioned","2018-11-07T10:01:53Z"],["dc.date.available","2018-11-07T10:01:53Z"],["dc.date.issued","2015"],["dc.description.abstract","Giant-cell myocarditis (GCM) is known as a rare, rapidly progressive, and frequently fatal myocardial disease in young and middle-aged adults. We report about a 76 year old male patient who underwent implantation with a biventricular Berlin Heart Excor system at the age of 74 due to acute biventricular heart failure caused by giant-cell myocarditis. The implantation was without any surgical problems; however, a difficulty was the immunosuppressive therapy after implantation. Meanwhile the patient is 76 years old and lives with circulatory support for about 3 years without major adverse events. Also, in terms of mobility in old age there are no major limitations. It seems that in even selected elderly patients an implantation of a long term support with the biventricular Berlin Heart Excor is a useful therapeutic option with an acceptable outcome."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2015"],["dc.identifier.doi","10.1186/s13019-015-0218-9"],["dc.identifier.isi","000350433300001"],["dc.identifier.pmid","25637129"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13464"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/38121"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1749-8090"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Long term biventricular support with Berlin Heart Excor in a Septuagenarian with giant-cell myocarditis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e000182"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Open Heart"],["dc.bibliographiccitation.volume","2"],["dc.contributor.author","Seegers, Joachim"],["dc.contributor.author","Zabel, Markus"],["dc.contributor.author","Grüter, Timo"],["dc.contributor.author","Ammermann, Antje"],["dc.contributor.author","Weber-Krüger, Mark"],["dc.contributor.author","Edelmann, Frank"],["dc.contributor.author","Gelbrich, Götz"],["dc.contributor.author","Binder, Lutz"],["dc.contributor.author","Herrmann-Lingen, Christoph"],["dc.contributor.author","Gröschel, Klaus"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Pieske, Burkert"],["dc.contributor.author","Wachter, Rolf"],["dc.date.accessioned","2017-09-07T11:52:34Z"],["dc.date.available","2017-09-07T11:52:34Z"],["dc.date.issued","2015"],["dc.identifier.doi","10.1136/openhrt-2014-000182"],["dc.identifier.gro","3144967"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13598"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/2650"],["dc.notes.intern","Crossref Import"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","public"],["dc.relation.issn","2053-3624"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.title","Natriuretic peptides for the detection of paroxysmal atrial fibrillation"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","59"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","ESC Heart Failure"],["dc.bibliographiccitation.lastpage","74"],["dc.bibliographiccitation.volume","1"],["dc.contributor.author","Nolte, Kathleen"],["dc.contributor.author","Schwarz, Silja"],["dc.contributor.author","Gelbrich, Götz"],["dc.contributor.author","Mensching, Steffen"],["dc.contributor.author","Siegmund, Friederike"],["dc.contributor.author","Wachter, Rolf"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Düngen, Hans-Dirk"],["dc.contributor.author","Herrmann-Lingen, Christoph"],["dc.contributor.author","Halle, Martin"],["dc.contributor.author","Pieske, Burkert"],["dc.contributor.author","Edelmann, Frank"],["dc.date.accessioned","2019-07-09T11:41:03Z"],["dc.date.available","2019-07-09T11:41:03Z"],["dc.date.issued","2014"],["dc.description.abstract","Background The long-term effects of exercise training (ET) in diastolic dysfunction (DD) and heart failure with preserved ejection fraction (HFpEF) are unknown. The present study compared the long-term effects of ET on exercise capacity, diastolic function, and quality of life (QoL) in patients with DD vs. HFpEF. Methods A total of n=43 patients with asymptomatic DD (n=19) or HFpEF [DD and New York Heart Association (NYHA) ≥II, n=24] and left ventricular ejection fraction ≥50% performed a combined endurance/resistance training over 6months (2–3/week) on top of usual care. Cardiopulmonary exercise testing, echocardiography, and QoL were obtained at baseline and follow-up. Results Patients were 62±8 years old (37% female). In the HFpEF group, 67% of patients were in NYHA class II (33% in NYHA III). Exercise capacity (peak oxygen consumption, peak VO2) differed at baseline (DD 29.2±8.7mL/min/kg vs. HFpEF 17.8±4.6 mL/min/kg; P=0.004). After 6months, peak VO2 increased significantly (P<0.044) to 19.7±5.8 mL/min/kg in the HFpEF group and also in the DD group (to 32.8±8.5mL/min/kg; P<0.002) with no overall difference between the groups (P=0.217). E/e′ ratio (left ventricular filling index) decreased from 12.2±3.5 to 10.1±3.0 (P<0.002) in patients with HFpEFand also in patients with DD (10.7±3.1 vs. 9.5±2.3; P=0.03; difference between groups P=0.210). In contrast, left atrial volume index decreased in the HFpEF group (P<0.001) but remained stable within the DD group (difference between groups P=0.015). After 6 months, physical QoL (Minnesota living with heart failure Questionnaire, 36-item short form health survey), general health perception, and 9-item patient health questionnaire score only improved in HFpEF (P<0.05). In contrast, vitality improved in both groups (difference between groups P=0.708). Conclusion A structured 6 months ET programme effectively improves exercise capacity and diastolic function in patients with DD and overt HFpEF. Therefore, controlled lifestylemodification with physical activity is effective both in DD and HFpEF."],["dc.identifier.doi","10.1002/ehf2.12007"],["dc.identifier.fs","610857"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11651"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58349"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1879-0844"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/4.0"],["dc.title","Effects of long-term endurance and resistance training on diastolic function, exercise capacity, and quality of life in asymptomatic diastolic dysfunction vs. heart failure with preserved ejection fraction"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.journal","The Open Clinical Trials Journal, 2010, 2, 1-7"],["dc.bibliographiccitation.lastpage","7"],["dc.bibliographiccitation.volume","2"],["dc.contributor.author","Neumann, Till"],["dc.contributor.author","Sundermeyer, Andreas"],["dc.contributor.author","Esser, Stefan"],["dc.contributor.author","Potthoff, Anja"],["dc.contributor.author","Hower, Martin"],["dc.contributor.author","Ingulf, Becker-Boost"],["dc.contributor.author","Ross, Birgit"],["dc.contributor.author","Jablonka, Robert"],["dc.contributor.author","Neuhaus, Katrin"],["dc.contributor.author","Neumann, Anja"],["dc.contributor.author","Reinsch, Nico"],["dc.contributor.author","Wachter, Rolf"],["dc.contributor.author","Müller-Tasch, Thomas"],["dc.contributor.author","Mehrhof, Felix"],["dc.contributor.author","Prettin, Christiane"],["dc.contributor.author","Gelbrich, Götz"],["dc.contributor.author","Maisch, Bernhard"],["dc.contributor.author","Brockmeyer, Norbert"],["dc.contributor.author","Wasem, Jürgen"],["dc.contributor.author","Dietz, Rainer"],["dc.contributor.author","Erbel, Raimund"],["dc.date.accessioned","2019-07-09T11:53:11Z"],["dc.date.available","2019-07-09T11:53:11Z"],["dc.date.issued","2010"],["dc.description.abstract","Background: An increased life span and the amount of cardiovascular risk factors necessitate a closer look on cardiac diseases in the population of human immunodeficiency virus (HIV) – infected subjects. Therefore, we launched a cardiology driven study analyzing HIV-associated diseases supported by the federal ministry of research. Methods: The HIV-HEART (HIV-infection and HEART disease) study is a prospective and multicenter cohort study performed in an urban area. The study comprehends standardized non-invasive cardiology tests of cardiac diseases, such as laboratory parameter, electrocardiogram, echocardiography and an endurance testing by a six-minute walk test. Results: In a 20 month recruiting period 802 HIV-infected patients (age: 44,2 ± 10,3 years; male: 83,4%) were included into the HIV-HEART Study. Duration of HIV-infection since initial diagnosis was 7,6 ± 5,8 years. Virus load was in 65,6% less than 50 copies/ml and CD4 - cell count (508,8 ± 300,6 cells/􀀁l) was more than 500 cells/􀀁l in 42,6%. A reduced CD4 – cell count between 200 and 499 cells/􀀁l or less than 200 cells/􀀁l was present in 45% and 12, 4%, respectively. Of all participants, 85,2% received antiretroviral therapy, most of these patients NRTIs (96,8%), followed by PIs (48,5%), and NNRTIs (45,7%). Conclusions: The characteristics of the HIV-HEART Study cohort are comparable to other national or international cohort registers on HIV-infected persons, performed in industrialized countries. Therefore, the HIV-HEART Study will be able to yield reliable data on the performance of HIV-associated diseases. (Clinical Trials NCT01119729)."],["dc.identifier.doi","10.2174/1876821001001020001"],["dc.identifier.fs","576761"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6976"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/60358"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1876-8210"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","Recruiting and Baseline of the HIV-HEART Study: A Prospective, Multicenter Trial to Analyze Cardiac Diseases in HIV-Infected Patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","14"],["dc.bibliographiccitation.journal","BMC Family Practice"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Koschack, Janka"],["dc.contributor.author","Scherer, Martin"],["dc.contributor.author","Luers, Claus"],["dc.contributor.author","Kochen, Michael M."],["dc.contributor.author","Wetzel, Dirk"],["dc.contributor.author","Kleta, Sibylle"],["dc.contributor.author","Pouwels, Claudia"],["dc.contributor.author","Wachter, R. Rolf"],["dc.contributor.author","Herrmann-Lingen, Christoph"],["dc.contributor.author","Pieske, Burkert M."],["dc.contributor.author","Binder, Lutz"],["dc.date.accessioned","2018-11-07T11:18:13Z"],["dc.date.available","2018-11-07T11:18:13Z"],["dc.date.issued","2008"],["dc.description.abstract","Background: Screening of primary care patients at risk for left ventricular systolic dysfunction by a simple blood-test might reduce referral rates for echocardiography. Whether or not natriuretic peptide testing is a useful and cost-effective diagnostic instrument in primary care settings, however, is still a matter of debate. Methods: N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, clinical information, and echocardiographic data of left ventricular systolic function were collected in 542 family practice patients with at least one cardiovascular risk factor. We determined the diagnostic power of the NT-proBNP assessment in ruling out left ventricular systolic dysfunction and compared it to a risk score derived from a logistic regression model of easily acquired clinical information. Results: 23 of 542 patients showed left ventricular systolic dysfunction. Both NT-proBNP and the clinical risk score consisting of dyspnea at exertion and ankle swelling, coronary artery disease and diuretic treatment showed excellent diagnostic power for ruling out left ventricular systolic dysfunction. AUC of NT-proBNP was 0.83 (95% CI, 0.75 to 0.92) with a sensitivity of 0.91 (95% CI, 0.71 to 0.98) and a specificity of 0.46 (95% CI, 0.41 to 0.50). AUC of the clinical risk score was 0.85 (95% CI, 0.79 to 0.91) with a sensitivity of 0.91 (95% CI, 0.71 to 0.98) and a specificity of 0.64 (95% CI, 0.59 to 0.67). 148 misclassifications using NT-proBNP and 55 using the clinical risk score revealed a significant difference (McNemar test; p < 0.001) that was based on the higher specificity of the clinical risk score. Conclusion: The evaluation of clinical information is at least as effective as NT-proBNP testing in ruling out left ventricular systolic dysfunction in family practice patients at risk. If these results are confirmed in larger cohorts and in different samples, family physicians should be encouraged to rely on the diagnostic power of the clinical information from their patients."],["dc.identifier.doi","10.1186/1471-2296-9-14"],["dc.identifier.isi","000254051900001"],["dc.identifier.pmid","18298821"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/8928"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/54989"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","1471-2296"],["dc.relation.orgunit","Institut für Allgemeinmedizin"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Natriuretic peptide vs. clinical information for diagnosis of left ventricular systolic dysfunction in primary care"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","588"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","European Journal of Heart Failure"],["dc.bibliographiccitation.lastpage","597"],["dc.bibliographiccitation.volume","21"],["dc.contributor.author","Wachter, Rolf"],["dc.contributor.author","Fonseca, Ana F."],["dc.contributor.author","Balas, Bogdan"],["dc.contributor.author","Kap, Elisabeth"],["dc.contributor.author","Engelhard, Johanna"],["dc.contributor.author","Schlienger, Raymond"],["dc.contributor.author","Klebs, Sven"],["dc.contributor.author","Wirta, Sara Bruce"],["dc.contributor.author","Kostev, Karel"],["dc.date.accessioned","2019-09-30T14:05:10Z"],["dc.date.accessioned","2021-10-27T13:21:21Z"],["dc.date.available","2019-09-30T14:05:10Z"],["dc.date.available","2021-10-27T13:21:21Z"],["dc.date.issued","2019"],["dc.description.abstract","AIMS: To analyse real-world treatment patterns of sacubitril/valsartan (sac/val) using data from a pharmacy database in Germany. METHODS AND RESULTS: A retrospective cohort study of 26 191 adult patients (aged ≥ 18 years) in the IMS® longitudinal prescriptions database in Germany who were dispensed sac/val from January 2016 to June 2017 was conducted. The analysis included sac/val dose titration assessed in the 6 months from first sac/val prescription; prescriptions of concomitant cardiovascular medications in the 6 months pre- and post-index and compliance and persistence during 12 months post-index. Two-thirds of patients were prescribed the lowest sac/val dose of 50 mg twice daily (b.i.d.) at index and up-titration during the first 6 months was attempted in 41% of these patients. Ten percent of patients prescribed 200 mg b.i.d. at index had to be stably down-titrated; among patients prescribed 50 or 100 mg b.i.d. at index that were up-titrated, > 80% remained on the higher dose. Overall, the mean daily diuretic dose decreased by 25% after initiation of sac/val. High compliance and persistence rates were observed across sac/val doses, increasing with higher sac/val dose at index. Prior dose of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker had only minor impact on first sac/val dose, compliance and persistence. CONCLUSIONS: Most patients prescribed sac/val are not initiated on the recommended dose nor up-titrated as recommended by the EU Summary of Product Characteristics. Initiation of sac/val was associated with high persistence and compliance and a dose reduction of diuretics. Barriers to up-titration must be explored."],["dc.identifier.doi","10.1002/ejhf.1465"],["dc.identifier.pmid","30972918"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16444"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/92015"],["dc.language.iso","en"],["dc.notes.intern","Migrated from goescholar"],["dc.relation.eissn","1879-0844"],["dc.relation.issn","1879-0844"],["dc.relation.issn","1388-9842"],["dc.relation.orgunit","Universitätsmedizin Göttingen"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/4.0"],["dc.subject.ddc","610"],["dc.title","Real‐world treatment patterns of sacubitril/valsartan: a longitudinal cohort study in Germany"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e0216530"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","PLoS One"],["dc.bibliographiccitation.volume","14"],["dc.contributor.author","Wasser, Katrin"],["dc.contributor.author","Weber-Krüger, Mark"],["dc.contributor.author","Jürries, Falko"],["dc.contributor.author","Liman, Jan"],["dc.contributor.author","Hamann, Gerhard F."],["dc.contributor.author","Kermer, Pawel"],["dc.contributor.author","Uphaus, Timo"],["dc.contributor.author","Protsenko, Evgeny"],["dc.contributor.author","Seegers, Joachim"],["dc.contributor.author","Mende, Meinhard"],["dc.contributor.author","Gröschel, Klaus"],["dc.contributor.author","Wachter, Rolf"],["dc.date.accessioned","2019-07-09T11:51:30Z"],["dc.date.available","2019-07-09T11:51:30Z"],["dc.date.issued","2019"],["dc.description.abstract","BACKGROUND: The cardiac diagnostic workup of stroke patients, especially the value of echocardiography and enhanced and prolonged Holter-ECG monitoring, is still a matter of debate. We aimed to analyse the impact of pathologies detected by echocardiography and ECG monitoring on therapeutic decisions and prognosis. METHODS: Find-AFRANDOMISED was a prospective multicenter study which randomised 398 acute ischemic stroke patients ≥ 60 years to enhanced and prolonged Holter-ECG monitoring or usual stroke unit care. This substudy compared therapeutic consequences of echocardiography and routine Holter-ECG or enhanced and prolonged Holter-ECG monitoring, respectively, and prognosis of patients with or without pathologic findings in echocardiography or Holter-ECG monitoring. RESULTS: 50.3% received enhanced and prolonged Holter-ECG monitoring and 49.7% routine ECG monitoring. 82.9% underwent transthoracic echocardiography (TTE), 38.9% transesophageal echocardiography (TEE) and 25.6% both procedures. 14/89 TEE pathologies and 1/90 TTE pathology led to a change in therapy, resulting in a number needed to change decision (NNCD) of 12 and 330 (p < 0.001), respectively. In comparison, enhanced and prolonged Holter-ECG monitoring found atrial fibrillation (AF) in 27 of 200 patients, and routine ECG monitoring in twelve of 198 patients, leading to therapeutic changes in all patients (NNCD 8 and 17, respectively, p < 0.001). CONCLUSIONS: Most changes in therapeutic decisions were triggered by enhanced and prolonged Holter-ECG monitoring, which should therefore play a more prominent role in future guidelines. Echocardiography identifies a patient group at high cardiovascular risk, but rarely result in therapeutic changes. Whether this patient group requires further cardiovascular workup remains unknown. This should be further investigated by interdisciplinary neurocardiologic teams and in appropriate future trials."],["dc.identifier.doi","10.1371/journal.pone.0216530"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16141"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59961"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject.ddc","610"],["dc.title","The cardiac diagnostic work-up in stroke patients—A subanalysis of the Find-AFRANDOMISED trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","875"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Clinical Research in Cardiology"],["dc.bibliographiccitation.lastpage","884"],["dc.bibliographiccitation.volume","102"],["dc.contributor.author","Mayer, Felix"],["dc.contributor.author","Stahrenberg, Raoul"],["dc.contributor.author","Groeschel, Klaus"],["dc.contributor.author","Mostardt, Sarah"],["dc.contributor.author","Biermann, Janine"],["dc.contributor.author","Edelmann, Frank T."],["dc.contributor.author","Liman, Jan"],["dc.contributor.author","Wasem, Juergen"],["dc.contributor.author","Goehler, Alexander"],["dc.contributor.author","Wachter, R. Rolf"],["dc.contributor.author","Neumann, Anja"],["dc.date.accessioned","2018-11-07T09:17:18Z"],["dc.date.available","2018-11-07T09:17:18Z"],["dc.date.issued","2013"],["dc.description.abstract","Prolonged Holter monitoring of patients with cerebral ischemia increases the detection rate of paroxysmal atrial fibrillation (PAF); this leads to improved antithrombotic regimens aimed at preventing recurrent ischemic strokes. The aim of this study was to compare a 7-day-Holter monitoring (7-d-Holter) alone or in combination with prior selection via transthoracic echocardiography (TTE) to a standard 24-h-Holter using a cost-utility analysis. Lifetime cost, quality-adjusted life years (QALY), and incremental cost-effectiveness ratios (ICER) were estimated for a cohort of patients with acute cerebral ischemia and no contraindication to oral anticoagulation. A Markov model was developed to simulate the long-term course and progression of cerebral ischemia considering the different diagnostic algorithms (24-h-Holter, 7-d-Holter, 7-d-Holter after preselection by TTE). Clinical data for these algorithms were derived from the prospective observational Find-AF study (ISRCTN 46104198). Predicted lifelong discounted costs were 33,837 a,not sign for patients diagnosed by the 7-d-Holter and 33,852 a,not sign by the standard 24-h-Holter. Cumulated QALYs were 3.868 for the 7-d-Holter compared to 3.844 for the 24-h-Holter. The 7-d-Holter dominated the 24-h-Holter in the base-case scenario and remained cost-effective in extensive sensitivity analysis of key input parameter with a maximum of 8,354 a,not sign/QALY gained. Preselecting patients for the 7-d-Holter had no positive effect on the cost-effectiveness. A 7-d-Holter to detect PAF in patients with cerebral ischemia is cost-effective. It increases the detection which leads to improved antithrombotic regimens; therefore, it avoids recurrent strokes, saves future costs, and decreases quality of life impairment. Preselecting patients by TTE does not improve cost-effectiveness."],["dc.description.sponsorship","Medtronic"],["dc.identifier.doi","10.1007/s00392-013-0601-2"],["dc.identifier.isi","000327208800003"],["dc.identifier.pmid","23904073"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11170"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28131"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Heidelberg"],["dc.relation.issn","1861-0692"],["dc.relation.issn","1861-0684"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Cost-effectiveness of 7-day-Holter monitoring alone or in combination with transthoracic echocardiography in patients with cerebral ischemia"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]